Alterations in microbiota of patients with COVID-19: implications for therapeutic interventions

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recently caused a global pandemic, resulting in more than 702 million people being infected and over 6.9 million deaths. Patients with coronavirus disease (COVID-19) may suffer from diarrhea, sleep disorders, depression, and even cognitive impairment, which is associated with long COVID during recovery. However, there remains no consensus on effective treatment methods. Studies have found that patients with COVID-19 have alterations in microbiota and their metabolites, particularly in the gut, which may be involved in the regulation of immune responses. Consumption of probiotics may alleviate the discomfort caused by inflammation and oxidative stress. However, the pathophysiological process underlying the alleviation of COVID-19-related symptoms and complications by targeting the microbiota remains unclear. In the current study, we summarize the latest research and evidence on the COVID-19 pandemic, together with symptoms of SARS-CoV-2 and vaccine use, with a focus on the relationship between microbiota alterations and COVID-19-related symptoms and vaccine use. This work provides evidence that probiotic-based interventions may improve COVID-19 symptoms by regulating gut microbiota and systemic immunity. Probiotics may also be used as adjuvants to improve vaccine efficacy.

Keywords

COVID-19 / gut microbiota / immunity / probiotics / vaccine

References

1	Worldometers.info. COVID-19 Coronavirus Pandemic. Published February 6, 2024. Accessed February 6, 2024.
2	B Bowe, Y Xie, Z Al-Aly. Postacute sequelae of COVID-19 at 2 years. Nat Med. 2023;29(9):2347-2357.
3	T Thaweethai, SE Jolley, EW Karlson, et al. Development of a definition of postacute sequelae of SARS-CoV-2 infection. JAMA. 2023;329(22):1934-1946.
4	R Wesselingh. Prevalence, pathogenesis and spectrum of neurological symptoms in COVID-19 and post-COVID-19 syndrome: a narrative review. Med J Aust. 2023;219(5):230-236.
5	YJ Chee, BE Fan, BE Young, R Dalan, DC Lye. Clinical trials on the pharmacological treatment of long COVID: a systematic review. J Med Virol. 2023;95(1):e28289.
6	G Lui, G Guaraldi. Drug treatment of COVID-19 infection. Curr Opin Pulm Med. 2023;29(3):174-183.
7	E Ammirati, JJ Moslehi. Diagnosis and treatment of acute myocarditis: a review. JAMA. 2023;329(13):1098-1113.
8	P Malik, K Patel, C Pinto, et al. Post-acute COVID-19 syndrome (PCS) and health-related quality of life (HRQoL)-A systematic review and meta-analysis. J Med Virol. 2022;94(1):253-262.
9	Q Liu, J Mak, Q Su, et al. Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome. Gut. 2022;71(3):544-552.
10	T Zuo, F Zhang, G Lui, et al. Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. Gastroenterology. 2020;159(3):944-955. e8.
11	YK Yeoh, T Zuo, GC Lui, et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. 2021;70(4):698-706.
12	KL Cheong, S Chen, B Teng, S Veeraperumal, S Zhong, K Tan. Oligosaccharides as potential regulators of gut microbiota and intestinal health in post-COVID-19 management. Pharmaceuticals (Basel). 2023;16(6):860.
13	PV Markov, M Ghafari, M Beer, et al. The evolution of SARS-CoV-2. Nat Rev Microbiol. 2023;21(6):361-379.
14	IA Kodsi, DE Rayes, J Koweyes, et al. Tracking SARS-CoV-2 variants during the 2023 flu season and beyond in Lebanon. Virus Res. 2024;339:199289.
15	X Zhang, X Deng, L Zhang, et al. Single-cell RNA sequencing analysis of lung cells in COVID-19 patients with diabetes, hypertension, and comorbid diabetes-hypertension. Front Endocrinol (Lausanne). 2023;14:1258646.
16	S Mei, Y Zou, S Jiang, et al. Highly potent dual-targeting angiotensin-converting enzyme 2 (ACE2) and Neuropilin-1 (NRP1) peptides: a promising broad-spectrum therapeutic strategy against SARS-CoV-2 infection. Eur J Med Chem. 2024;263:115908.
17	MJ Patton, A Gaggar, M Might, N Erdmann, CJ Orihuela, KS Harrod. Community-acquired bacterial coinfections and COVID-19. Physiol Rev. 2024;104(1):1-21.
18	S Dai, T Cao, H Shen, et al. Landscape of molecular crosstalk between SARS-CoV-2 infection and cardiovascular diseases: emphasis on mitochondrial dysfunction and immune-inflammation. J Transl Med. 2023;21(1):915.
19	K Hon, A Leung, K Leung, A Wong. Impact of “long covid” on children: global and Hong Kong perspectives. Curr Pediatr Rev. 2024;20(1):59-65.
20	A Yisimayi, W Song, J Wang, et al. Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting. Nature. 2024;625(7993):148-156.
21	MC Gulliford, CJ Steves. Access to COVID-19 vaccination and COVID-19-related hospital admissions and mortality. Lancet. 2024. S0140-6736(23)02622-02623.
22	MS Alkodaymi, OA Omrani, NA Fawzy, et al. Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis. Clin Microbiol Infect. 2022;28(5):657-666.
23	BY Choi, AR Grace, J Tsai. Heterogeneity of COVID-19 symptoms and associated factors: longitudinal analysis of laboratory-confirmed COVID-19 cases in San Antonio. PLoS One. 2023;18(12):e0295418.
24	C Fernández-de-Las-Pe?as, I Cancela-Cilleruelo, P Moro-López-Menchero, et al. Exploring the trajectory curve of long-term musculoskeletal post-COVID pain symptoms in hospitalized COVID-19 survivors: a multicenter study. Pain. 2023;164(2):413-420.
25	C Fernández-de-Las-Pe?as, J Torres-Macho, C Guijarro, JD Martín-Guerrero, OJ Pellicer-Valero, G Plaza-Manzano. Trajectory of gastrointestinal symptoms in previously hospitalized COVID-19 survivors: the long COVID experience multicenter study. Viruses. 2023;15(5):1134.
26	C Huang, L Huang, Y Wang, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2023;401(10393):e21-e33.
27	CE Hastie, DJ Lowe, A McAuley, et al. True prevalence of long-COVID in a nationwide, population cohort study. Nat Commun. 2023;14(1):7892.
28	HE Davis, L McCorkell, JM Vogel, EJ Topol. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133-146.
29	L Lu, L Chen, P Wang, et al. Neurological complications during the Omicron COVID-19 wave in China: a cohort study. Eur J Neurol. 2024;31(1):e16096.
30	H Kandemir, GA Bülbül, E Kirti?, S Güney, CY Sanhal, ?? Mendilcio?lu. Evaluation of long-COVID symptoms in women infected with SARS-CoV-2 during pregnancy. Int J Gynaecol Obstet. 2024;164(1):148-156.
31	CJ Atchison, B Davies, E Cooper, et al. Long-term health impacts of COVID-19 among 242,712 adults in England. Nat Commun. 2023;14(1):6588.
32	T Stephenson, SM Pinto Pereira, R Shafran, et al. Physical and mental health 3 months after SARS-CoV-2 infection (long COVID) among adolescents in England (CLoCk): a national matched cohort study. Lancet Child Adolesc Health. 2022;6(4):230-239.
33	AG Bertollo, AC Leite Galvan, ME Dama Mingoti, C Dallagnol, ZM Ignácio. Impact of COVID-19 on anxiety and depression—biopsychosocial factors. CNS Neurol Disord Drug Targets. 2024;23(1):122-133.
34	A Nalbandian, K Sehgal, A Gupta, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601-615.
35	F Ceban, S Ling, L Lui, et al. Fatigue and cognitive impairment in post-COVID-19 syndrome: a systematic review and meta-analysis. Brain Behav Immun. 2022;101:93-135.
36	N Latronico, E Peli, S Calza, et al. Physical, cognitive and mental health outcomes in 1-year survivors of COVID-19-associated ARDS. Thorax. 2022;77(3):300-303.
37	G Douaud, S Lee, F Alfaro-Almagro, et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature. 2022;604(7907):697-707.
38	AC Yang, F Kern, PM Losada, et al. Dysregulation of brain and choroid plexus cell types in severe COVID-19. Nature. 2021;595(7868):565-571.
39	S Alonso-Lana, M Marquié, A Ruiz, M Boada. Cognitive and neuropsychiatric manifestations of COVID-19 and effects on elderly individuals with dementia. Front Aging Neurosci. 2020;12:588872.
40	Y Zhao, W Li, W Lukiw. Ubiquity of the SARS-CoV-2 receptor ACE2 and upregulation in limbic regions of Alzheimer's disease brain. Folia Neuropathol. 2021;59(3):232-238.
41	P Pérez-Rodríguez, M Díaz de Bustamante, S Aparicio Mollá, et al. Functional, cognitive, and nutritional decline in 435 elderly nursing home residents after the first wave of the COVID-19 pandemic. Eur Geriatr Med. 2021;12(6):1137-1145.
42	J Gu, Q Liu, J Zhang, S Xu. COVID-19 and trained immunity: the inflammatory burden of long covid. Front Immunol. 2023;14:1294959.
43	Y Qiu, C Mo, S Xu, et al. Research progress on perioperative blood-brain barrier damage and its potential mechanism. Front Cell Dev Biol. 2023;11:1174043.
44	CS von Bartheld, L Wang. Prevalence of olfactory dysfunction with the omicron variant of SARS-CoV-2: a systematic review and meta-analysis. Cells. 2023;12(3):430.
45	S Chen, J Liang, D Chen, et al. Cerebrospinal fluid metabolomic and proteomic characterization of neurologic post-acute sequelae of SARS-CoV-2 infection. Brain Behav Immun. 2024;115:209-222.
46	J Meinhardt, S Streit, C Dittmayer, RV Manitius, H Radbruch, FL Heppner. The neurobiology of SARS-CoV-2 infection. Nat Rev Neurosci. 2024;25(1):30-42.
47	E Xu, Y Xie, Z Al-Aly. Long-term neurologic outcomes of COVID-19. Nat Med. 2022;28(11):2406-2415.
48	T Dondaine, F Ruthmann, F Vuotto, et al. Long-term cognitive impairments following COVID-19: a possible impact of hypoxia. J Neurol. 2022;269(8):3982-3989.
49	M Jahani, S Dokaneheifard, K Mansouri. Hypoxia: a key feature of COVID-19 launching activation of HIF-1 and cytokine storm. J Inflamm (Lond). 2020;17:33.
50	ZO Serebrovska, EY Chong, TV Serebrovska, LV Tumanovska, XiL Hypoxia . HIF-1α, and COVID-19: from pathogenic factors to potential therapeutic targets. Acta Pharmacol Sin. 2020;41(12):1539-1546.
51	AL Soung, A Vanderheiden, AS Nordvig, et al. COVID-19 induces CNS cytokine expression and loss of hippocampal neurogenesis. Brain. 2022;145(12):4193-4201.
52	A Fernández-Casta?eda, P Lu, AC Geraghty, et al. Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation. Cell. 2022;185(14):2452-2468.
53	M Monje, A Iwasaki. The neurobiology of long COVID. Neuron. 2022;110(21):3484-3496.
54	FL Fontes-Dantas, GG Fernandes, EG Gutman, et al. SARS-CoV-2 Spike protein induces TLR4-mediated long-term cognitive dysfunction recapitulating post-COVID-19 syndrome in mice. Cell Rep. 2023;42(3):112189.
55	V Venkataramani, F Winkler. Cognitive deficits in long COVID-19. N Engl J Med. 2022;387(19):1813-1815.
56	J Yang, W Wang, Z Chen, et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature. 2020;586(7830):572-577.
57	C He, J Yang, W Hong, et al. A self-assembled trimeric protein vaccine induces protective immunity against Omicron variant. Nat Commun. 2022;13(1):5459.
58	G Regev-Yochay, T Gonen, M Gilboa, et al. Efficacy of a fourth dose of COVID-19 mRNA vaccine against omicron. N Engl J Med. 2022;386(14):1377-1380.
59	H Wang, Y Zhang, B Huang, et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell. 2020;182(3):713-721. e9.
60	OT Ranzani, M Hitchings, M Dorion, et al. Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated pandemic of covid-19 in Brazil: test negative case-control study. BMJ. 2021;374:n2015.
61	M Voysey, S Clemens, SA Madhi, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-111.
62	J Sadoff, G Gray, A Vandebosch, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384(23):2187-2201.
63	Y Chen, W Yang, F Chen, L Cui. COVID-19 and cognitive impairment: neuroinvasive and blood?brain barrier dysfunction. J Neuroinflammation. 2022;19(1):222.
64	CJ Chiew, M Premikha, CY Chong, et al. Effectiveness of primary series and booster vaccination against SARS-CoV-2 infection and hospitalisation among adolescents aged 12–17 years in Singapore: a national cohort study. Lancet Infect Dis. 2023;23(2):177-182.
65	C Arsenault, TP Lewis, NR Kapoor, et al. Health system quality and COVID-19 vaccination: a cross-sectional analysis in 14 countries. Lancet Glob Health. 2024;12(1):e156-e165.
66	JV Lazarus, K Wyka, TM White, et al. A survey of COVID-19 vaccine acceptance across 23 countries in 2022. Nat Med. 2023;29(2):366-375.
67	E Pairo-Castineira, K Rawlik, AD Bretherick, et al. GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19. Nature. 2023;617(7962):764-768.
68	A Kumar, RK Narayan, P Prasoon, et al. COVID-19 vaccination may enhance hippocampal neurogenesis in adults. Brain Behav Immun. 2023;107:87-89.
69	M Daly, E Robinson. Depression and anxiety during COVID-19. Lancet. 2022;399(10324):518.
70	CF Yung, D Pang, KQ Kam, et al. BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: a population-based cohort study. Lancet Child Adolesc Health. 2023;7(7):463-470.
71	F Yasmin, H Najeeb, U Naeem, et al. Adverse events following COVID-19 mRNA vaccines: a systematic review of cardiovascular complication, thrombosis, and thrombocytopenia. Immun Inflamm Dis. 2023;11(3):e807.
72	TA Stamm, J Partheymüller, E Mosor, et al. Determinants of COVID-19 vaccine fatigue. Nat Med. 2023;29(5):1164-1171.
73	R Rubin. Updated COVID-19 vaccine now available in US, recommended for everyone older than 6 months. JAMA. 2023;330(15):1420.
74	DM Simadibrata, E Lesmana, J Gunawan, EM Quigley, M Simadibrata. A systematic review of gut microbiota profile in COVID-19 patients and among those who have recovered from COVID-19. J Dig Dis. 2023;24(4):244-261.
75	B Zhou, X Pang, J Wu, T Liu, B Wang, H Cao. Gut microbiota in COVID-19: new insights from inside. Gut Microbes. 2023;15(1):2201157.
76	C álvarez-Santacruz, SD Tyrkalska, S Candel. The microbiota in long COVID. Int J Mol Sci. 2024;25(2):1330.
77	A Saviano, M Brigida, C Petruzziello, et al. Intestinal damage, inflammation and microbiota alteration during COVID-19 infection. Biomedicines. 2023;11(4):1014.
78	F Zhang, RI Lau, Q Liu, Q Su, F Chan, SC Ng. Gut microbiota in COVID-19: key microbial changes, potential mechanisms and clinical applications. Nat Rev Gastroenterol Hepatol. 2023;20(5):323-337.
79	E Sefik, R Qu, C Junqueira, et al. Inflammasome activation in infected macrophages drives COVID-19 pathology. Nature. 2022;606(7914):585-593.
80	KD Synodinou, MD Nikolaki, K Triantafyllou, AN Kasti. Immunomodulatory effects of probiotics on COVID-19 infection by targeting the gut-lung axis microbial cross-talk. Microorganisms. 2022;10(9):1764.
81	J Li, Q Jing, J Li, et al. Assessment of microbiota in the gut and upper respiratory tract associated with SARS-CoV-2 infection. Microbiome. 2023;11(1):38.
82	D Zhang, S Weng, C Xia, et al. Gastrointestinal symptoms of long COVID-19 related to the ectopic colonization of specific bacteria that move between the upper and lower alimentary tract and alterations in serum metabolites. BMC Med. 2023;21(1):264.
83	L Mancabelli, G Taurino, A Ticinesi, et al. Disentangling the interactions between nasopharyngeal and gut microbiome and their involvement in the modulation of COVID-19 infection. Microbiol Spectr. 2023;11(5):e0219423.
84	T Bose, Wasimuddin, V Acharya, et al. A cross-sectional study on the nasopharyngeal microbiota of individuals with SARS-CoV-2 infection across three COVID-19 waves in India. Front Microbiol. 2023;14:1238829.
85	S Candel, SD Tyrkalska, C álvarez-Santacruz, V Mulero. The nasopharyngeal microbiome in COVID-19. Emerg Microbes Infect. 2023;12(1):e2165970.
86	V Sencio, A Machelart, C Robil, et al. Alteration of the gut microbiota following SARS-CoV-2 infection correlates with disease severity in hamsters. Gut Microbes. 2022;14(1):2018900.
87	T Zhou, J Wu, Y Zeng, et al. SARS-CoV-2 triggered oxidative stress and abnormal energy metabolism in gut microbiota. MedComm. 2022;3(1):e112.
88	S Liu, Y Zhao, X Feng, H Xu. SARS-CoV-2 infection threatening intestinal health: a review of potential mechanisms and treatment strategies. Crit Rev Food Sci Nutr. 2023;63(33):12578-12596.
89	A Tursi, A Papa. Intestinal microbiome modulation during coronavirus disease 2019: another chance to manage the disease. Gastroenterology. 2022;162(7):2134.
90	F Zhang, Y Wan, T Zuo, et al. Prolonged impairment of short-chain fatty acid and l-isoleucine biosynthesis in gut microbiome in patients with COVID-19. Gastroenterology. 2022;162(2):548-561. e4.
91	Z Li, G Zhu, X Lei, et al. Genetic support of the causal association between gut microbiome and COVID-19: a bidirectional Mendelian randomization study. Front Immunol. 2023;14:1217615.
92	M Nagai, M Moriyama, C Ishii, et al. High body temperature increases gut microbiota-dependent host resistance to influenza A virus and SARS-CoV-2 infection. Nat Commun. 2023;14(1):3863.
93	M Tr?seid, JC Holter, K Holm, et al. Gut microbiota composition during hospitalization is associated with 60-day mortality after severe COVID-19. Crit Care. 2023;27(1):69.
94	A Mannan, MN Hoque, SH Noyon, et al. SARS-CoV-2 infection alters the gut microbiome in diabetes patients: a cross-sectional study from Bangladesh. J Med Virol. 2023;95(4):e28691.
95	HY Ng, WK Leung, KS Cheung. Association between gut microbiota and SARS-CoV-2 infection and vaccine immunogenicity. Microorganisms. 2023;11(2):452.
96	V Mendes de Almeida, DF Engel, MF Ricci, et al. Gut microbiota from patients with COVID-19 cause alterations in mice that resemble post-COVID symptoms. Gut Microbes. 2023;15(2):2249146.
97	C Brogna, V Viduto, M Fabrowski, et al. The importance of the gut microbiome in the pathogenesis and transmission of SARS-CoV-2. Gut Microbes. 2023;15(1):2244718.
98	J Li, TS Ghosh, R McCann, et al. Robust cross-cohort gut microbiome associations with COVID-19 severity. Gut Microbes. 2023;15(1):2242615.
99	G Ancona, L Alagna, C Alteri, et al. Gut and airway microbiota dysbiosis and their role in COVID-19 and long-COVID. Front Immunol. 2023;14:1080043.
100	NC Moreno-Corona, O López-Ortega, CA Pérez-Martínez, et al. Dynamics of the microbiota and its relationship with post-COVID-19 syndrome. Int J Mol Sci. 2023;24(19):14822.
101	H Xiang, QP Liu. Alterations of the gut microbiota in coronavirus disease 2019 and its therapeutic potential. World J Gastroenterol. 2022;28(47):6689-6701.
102	J Zhang, J Deng, J Li, et al. Changes of gut microbiota under different nutritional methods in elderly patients with severe COVID-19 and their relationship with prognosis. Front Immunol. 2023;14:1260112.
103	H Seong, JH Kim, YH Han, et al. Clinical implications of gut microbiota and cytokine responses in coronavirus disease prognosis. Front Immunol. 2023;14:1079277.
104	N Nagata, T Takeuchi, H Masuoka, et al. Human gut microbiota and its metabolites impact immune responses in COVID-19 and its complications. Gastroenterology. 2023;164(2):272-288.
105	J Song, Y Wu, X Yin, H Ma, J Zhang. The causal links between gut microbiota and COVID-19: a Mendelian randomization study. J Med Virol. 2023;95(5):e28784.
106	G Eleftheriotis, EP Tsounis, I Aggeletopoulou, et al. Alterations in gut immunological barrier in SARS-CoV-2 infection and their prognostic potential. Front Immunol. 2023;14:1129190.
107	W Shang, S Zhang, H Qian, et al. Association of gut microbiota with COVID-19 susceptibility and severity: a two-sample Mendelian randomization study. J Med Virol. 2023;95(4):e28734.
108	H Chen, B Ye, W Su, et al. The causal role of gut microbiota in susceptibility and severity of COVID-19: a bidirectional Mendelian randomization study. J Med Virol. 2023;95(7):e28880.
109	M Wang, Y Zhang, C Li, W Chang, L Zhang. The relationship between gut microbiota and COVID-19 progression: new insights into immunopathogenesis and treatment. Front Immunol. 2023;14:1180336.
110	VM Martín Giménez, J Modrego, D Gómez-Garre, W Manucha, N de Las Heras. Gut microbiota dysbiosis in COVID-19: modulation and approaches for prevention and therapy. Int J Mol Sci. 2023;24(15):12249.
111	IC Hwang, R Vasquez, JH Song, L Engstrand, VD Valeriano, DK Kang. Alterations in the gut microbiome and its metabolites are associated with the immune response to mucosal immunization with Lactiplantibacillus plantarum-displaying recombinant SARS-CoV-2 spike epitopes in mice. Front Cell Infect Microbiol. 2023;13:1242681.
112	Z Liang, N Wang, C Fan, et al. Disturbance of adaptive immunity system was accompanied by a decrease in plasma short-chain fatty acid for patients hospitalized during SARS-CoV-2 infection after COVID-19 vaccination. J Inflamm Res. 2023;16:5261-5272.
113	S Ahmadi Badi, S Tarashi, A Fateh, P Rohani, A Masotti, SD Siadat. From the role of microbiota in gut-lung axis to SARS-CoV-2 pathogenesis. Mediators Inflamm. 2021;2021:6611222.
114	AM Plummer, YL Matos, HC Lin, et al. Gut-brain pathogenesis of post-acute COVID-19 neurocognitive symptoms. Front Neurosci. 2023;17:1232480.
115	S Malan-Müller, M Valles-Colomer, T Palomo, JC Leza. The gut-microbiota-brain axis in a Spanish population in the aftermath of the COVID-19 pandemic: microbiota composition linked to anxiety, trauma, and depression profiles. Gut Microbes. 2023;15(1):2162306.
116	RG Xiong, J Li, J Cheng, et al. The role of gut microbiota in anxiety, depression, and other mental disorders as well as the protective effects of dietary components. Nutrients. 2023;15(14):3258.
117	Y Fu, Z Guo, Y Wang, et al. Single-nucleus RNA sequencing reveals the shared mechanisms inducing cognitive impairment between COVID-19 and Alzheimer's disease. Front Immunol. 2022;13:967356.
118	Y Zhou, J Xu, Y Hou, et al. Network medicine links SARS-CoV-2/COVID-19 infection to brain microvascular injury and neuroinflammation in dementia-like cognitive impairment. Alzheimers Res Ther. 2021;13(1):110.
119	ME Tremblay, C Madore, M Bordeleau, L Tian, A Verkhratsky. Neuropathobiology of COVID-19: the role for glia. Front Cell Neurosci. 2020;14:592214.
120	Samudyata, AO Oliveira, S Malwade, et al. SARS-CoV-2 promotes microglial synapse elimination in human brain organoids. Mol Psychiatry. 2022;27(10):3939-3950.
121	TE Poloni, V Medici, M Moretti, et al. COVID-19-related neuropathology and microglial activation in elderly with and without dementia. Brain Pathol. 2021;31(5):e12997.
122	J Matschke, M Lütgehetmann, C Hagel, et al. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol. 2020;19(11):919-929.
123	H Alexopoulos, E Magira, K Bitzogli, et al. Anti-SARS-CoV-2 antibodies in the CSF, blood-brain barrier dysfunction, and neurological outcome: studies in 8 stuporous and comatose patients. Neurol Neuroimmunol Neuroinflamm. 2020;7(6):e893.
124	C Franke, C Ferse, J Kreye, et al. High frequency of cerebrospinal fluid autoantibodies in COVID-19 patients with neurological symptoms. Brain Behav Immun. 2021;93:415-419.
125	C Franke, F Boesl, Y Goereci, et al. Association of cerebrospinal fluid brain-binding autoantibodies with cognitive impairment in post-COVID-19 syndrome. Brain Behav Immun. 2023;109:139-143.
126	ES Geanes, C LeMaster, ER Fraley, et al. Cross-reactive antibodies elicited to conserved epitopes on SARS-CoV-2 spike protein after infection and vaccination. Sci Rep. 2022;12(1):6496.
127	A Gasmi, P Kumar Mujawdiya, S Noor, S Piscopo, S Résimont, A Menzel. Increasing efficacy of covid-19 vaccines by lifestyle interventions. Arch Razi Inst. 2022;77(5):1527-1538.
128	A Romani, D Sergi, E Zauli, et al. Nutrients, herbal bioactive derivatives and commensal microbiota as tools to lower the risk of SARS-CoV-2 infection. Front Nutr. 2023;10:1152254.
129	Y Shen, Y Dong, J Jiao, P Wang, M Chen, J Li. BBIBP-CorV vaccination against the SARS-CoV-2 virus affects the gut microbiome. Vaccines (Basel). 2023;11(5):942.
130	S Zhao, K Lok, ZY Sin, et al. COVID-19 mRNA vaccine-mediated antibodies in human breast milk and their association with breast milk microbiota composition. NPJ Vaccines. 2023;8(1):151.
131	J Leung. Interaction between gut microbiota and COVID-19 and its vaccines. World J Gastroenterol. 2022;28(40):5801-5806.
132	M Hong, T Lan, Q Li, et al. A comprehensive perspective on the interaction between gut microbiota and COVID-19 vaccines. Gut Microbes. 2023;15(1):2233146.
133	M Han, Y Huang, H Gui, et al. Dynamic changes in host immune system and gut microbiota are associated with the production of SARS-CoV-2 antibodies. Gut. 2023;72(10):1996-1999.
134	B Tang, L Tang, W He, et al. Correlation of gut microbiota and metabolic functions with the antibody response to the BBIBP-CorV vaccine. Cell Rep Med. 2022;3(10):100752.
135	SC Ng, Y Peng, L Zhang, et al. Gut microbiota composition is associated with SARS-CoV-2 vaccine immunogenicity and adverse events. Gut. 2022;71(6):1106-1116.
136	G Huang, Y Mao, W Zhang, et al. Explore the changes of intestinal flora in patients with coronavirus disease 2019 based on bioinformatics. Front Cell Infect Microbiol. 2023;13:1265028.
137	EC Ale, AG Binetti. Role of probiotics, prebiotics, and synbiotics in the elderly: insights into their applications. Front Microbiol. 2021;12:631254.
138	M Vaezi, S Ravanshad, M Akbari Rad, H Zarrinfar, M Kabiri. The effect of synbiotic adjunct therapy on clinical and paraclinical outcomes in hospitalized COVID-19 patients: a randomized placebo-controlled trial. J Med Virol. 2023;95(2):e28463.
139	S Reino-Gelardo, M Palop-Cervera, N Aparisi-Valero, et al. Effect of an immune-boosting, antioxidant and anti-inflammatory food supplement in hospitalized COVID-19 patients: a prospective randomized pilot study. Nutrients. 2023;15(7):1736.
140	RA Forsg?rd, J Rode, K Lobenius-Palmér, et al. Limosilactobacillus reuteri DSM 17938 supplementation and SARS-CoV-2 specific antibody response in healthy adults: a randomized, triple-blinded, placebo-controlled trial. Gut Microbes. 2023;15(1):2229938.
141	P Gutiérrez-Castrellón, T Gandara-Martí, Y Abreu, AT Abreu, et al. Probiotic improves symptomatic and viral clearance in Covid19 outpatients: a randomized, quadruple-blinded, placebo-controlled trial. Gut Microbes. 2022;14(1):2018899.
142	A Saviano, A Potenza, V Siciliano, et al. COVID-19 pneumonia and gut inflammation: the role of a mix of three probiotic strains in reducing inflammatory markers and need for oxygen support. J Clin Med. 2022;11(13):3758.
143	I De Boeck, E Cauwenberghs, I Spacova, et al. Randomized, double-blind, placebo-controlled trial of a throat spray with selected Lactobacilli in COVID-19 outpatients. Microbiol Spectr. 2022;10(5):e0168222.
144	F Di Pierro, S Iqtadar, SU Mumtaz, et al. Clinical effects of Streptococcus salivarius K12 in hospitalized COVID-19 patients: results of a preliminary study. Microorganisms. 2022;10(10):1926.
145	A Nalbandian, AD Desai, EY Wan. Post-COVID-19 condition. Annu Rev Med. 2023;74:55-64.
146	TJ Hartung, C Neumann, T Bahmer, et al. Fatigue and cognitive impairment after COVID-19: a prospective multicentre study. EClinicalMedicine. 2022;53:101651.
147	YH Liu, YR Wang, QH Wang, et al. Post-infection cognitive impairments in a cohort of elderly patients with COVID-19. Mol Neurodegener. 2021;16(1):48.
148	YH Liu, Y Chen, QH Wang, et al. One-year trajectory of cognitive changes in older survivors of COVID-19 in Wuhan, China: a longitudinal cohort study. JAMA Neurol. 2022;79(5):509-517.
149	D Xavier-Santos, M Padilha, GA Fabiano, et al. Evidences and perspectives of the use of probiotics, prebiotics, synbiotics, and postbiotics as adjuvants for prevention and treatment of COVID-19: a bibliometric analysis and systematic review. Trends Food Sci Technol. 2022;120:174-192.
150	J Zhu, T Pitre, C Ching, D Zeraatkar, S Gruchy. Safety and efficacy of probiotic supplements as adjunctive therapies in patients with COVID-19: a systematic review and meta-analysis. PLoS One. 2023;18(3):e0278356.
151	E Giannoni, D Baud, VD Agri, GR Gibson, G Reid. Probiotics and COVID-19. Lancet Gastroenterol Hepatol. 2020;5(8):720-721.
152	CS Kim, L Cha, M Sim, et al. Probiotic supplementation improves cognitive function and mood with changes in gut microbiota in community-dwelling older adults: a randomized, double-blind, placebo-controlled, multicenter trial. J Gerontol A Biol Sci Med Sci. 2021;76(1):32-40.
153	A Rathi, SB Jadhav, N Shah. A randomized controlled trial of the efficacy of systemic enzymes and probiotics in the resolution of post-COVID fatigue. Medicines (Basel). 2021;8(9):47.
154	M Mozota, I Castro, N Gómez-Torres, et al. Administration of Ligilactobacillus salivarius MP101 in an elderly nursing home during the COVID-19 pandemic: immunological and nutritional impact. Foods. 2021;10(9):2149.
155	M Mozota, I Castro, N Gómez-Torres, et al. Administration of Ligilactobacillus salivarius CECT 30632 to elderly during the COVID-19 pandemic: nasal and fecal metataxonomic analysis and fatty acid profiling. Front Microbiol. 2022;13:1052675.
156	A Catinean, A Sida, C Silvestru, GG Balan. Ongoing treatment with a spore-based probiotic containing five strains of bacillus improves outcomes of mild COVID-19. Nutrients. 2023;15(3):488.
157	V Nobile, F Puoci. Effect of a multi-strain probiotic supplementation to manage stress during the COVID-19 pandemic: a randomized, double-blind, placebo-controlled, cross-over clinical trial. Neuropsychobiology. 2023;82(2):61-71.
158	S Neris Almeida Viana, T do Reis Santos Pereira, J de Carvalho Alves, et al. Benefits of probiotic use on COVID-19: a systematic review and meta-analysis. Crit Rev Food Sci Nutr. 2022:1-13.
159	M Ray, A Manjunath, PM Halami. Effect of probiotics as an immune modulator for the management of COVID-19. Arch Microbiol. 2023;205(5):182.
160	N Akram, F Saeed, M Afzaal, et al. Gut microbiota and synbiotic foods: unveiling the relationship in COVID-19 perspective. Food Sci Nutr. 2023;11(3):1166-1177.
161	A Sohail, HA Cheema, MS Mithani, et al. Probiotics for the prevention and treatment of COVID-19: a rapid systematic review and meta-analysis. Front Nutr. 2023;10:1274122.
162	KS Batista, JG de Albuquerque, M Vasconcelos, et al. Probiotics and prebiotics: potential prevention and therapeutic target for nutritional management of COVID-19. Nutr Res Rev. 2023;36(2):181-198.
163	Y Tian, H Ran, X Wen, et al. Probiotics improve symptoms of patients with COVID-19 through gut-lung axis: a systematic review and meta-analysis. Front Nutr. 2023;10:1179432.
164	G Saxami, EN Kerezoudi, C Eliopoulos, D Arapoglou, A Kyriacou. The gut-organ axis within the human body: gut dysbiosis and the role of prebiotics. Life (Basel). 2023;13(10):2023.
165	PE Wischmeyer, H Tang, Y Ren, et al. Efficacy of probiotic treatment as post-exposure prophylaxis for COVID-19: a double-blind, placebo-controlled randomized trial. Clin Nutr. 2024;43(1):259-267.
166	HC Lau, SC Ng, J Yu. Targeting the gut microbiota in coronavirus disease 2019: hype or hope. Gastroenterology. 2022;162(1):9-16.
167	MF Alenazy, HI Aljohar, AR Alruwaili, et al. Gut microbiota dynamics in relation to long-COVID-19 syndrome: role of probiotics to combat psychiatric complications. Metabolites. 2022;12(10):912.
168	A Mardi, A Kamran, F Pourfarzi, et al. Potential of macronutrients and probiotics to boost immunity in patients with SARS-COV-2: a narrative review. Front Nutr. 2023;10:1161894.
169	G ?nning, C Montelius, M Hillman, N Larsson. Intake of Lactiplantibacillus plantarum HEAL9 improves cognition in moderately stressed subjects: a randomized controlled study. Nutrients. 2023;15(15):3466.
170	T Zhang, G Gao, LY Kwok, Z Sun. Gut microbiome-targeted therapies for Alzheimer's disease. Gut Microbes. 2023;15(2):2271613.
171	CS Kim, S Jung, GS Hwang, DM Shin. Gut microbiota indole-3-propionic acid mediates neuroprotective effect of probiotic consumption in healthy elderly: a randomized, double-blind, placebo-controlled, multicenter trial and in vitro study. Clin Nutr. 2023;42(6):1025-1033.
172	L Laterza, L Putignani, CR Settanni, et al. Ecology and machine learning-based classification models of gut microbiota and inflammatory markers may evaluate the effects of probiotic supplementation in patients recently recovered from COVID-19. Int J Mol Sci. 2023;24(7):6623.
173	HB Duindam, R Kessels, B van den Borst, P Pickkers, WF Abdo. Long-term cognitive performance and its relation to anti-inflammatory therapy in a cohort of survivors of severe COVID-19. Brain Behav Immun Health. 2022;25:100513.
174	A Bartos, J Weinerova, S Diondet, K Vales. Effect of human probiotics on memory, psychological and biological measures in elderly: a study protocol of bi-center, double-blind, randomized, placebo-controlled clinical trial (CleverAge Biota). Front Aging Neurosci. 2022;14:996234.
175	AL Ferreiro, J Choi, J Ryou, et al. Gut microbiome composition may be an indicator of preclinical Alzheimer's disease. Sci Transl Med. 2023;15(700):eabo2984.
176	L Kiani. Early microbiome changes in neurodegenerative disease. Nat Rev Neurol. 2023;19(8):458.
177	J Gon?alves, TJ Borges, A de Souza. Microbiota and the response to vaccines against respiratory virus. Front Immunol. 2022;13:889945.
178	GR Lunken, L Golding, A Schick, A Majdoubi, PM Lavoie, BA Vallance. Gut microbiome and dietary fibre intake strongly associate with IgG function and maturation following SARS-CoV-2 mRNA vaccination. Gut. 2023;73(1):208-210.
179	L Daddi, Y Dorsett, T Geng, et al. Baseline gut microbiome signatures correlate with immunogenicity of SARS-CoV-2 mRNA vaccines. Int J Mol Sci. 2023;24(14):11703.
180	Y Peng, L Zhang, C Mok, et al. Baseline gut microbiota and metabolome predict durable immunogenicity to SARS-CoV-2 vaccines. Signal Transduct Target Ther. 2023;8(1):373.
181	JL Alexander, BH Mullish, NP Danckert, et al. The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients. EBioMedicine. 2023;88:104430.
182	M Biancolella, VL Colona, L Luzzatto, et al. COVID-19 annual update: a narrative review. Hum Genomics. 2023;17(1):68.
183	S Oh, H Seo. Dietary intervention with functional foods modulating gut microbiota for improving the efficacy of COVID-19 vaccines. Heliyon. 2023;9(5):e15668.
184	B Huang, J Wang, L Li. Recent five-year progress in the impact of gut microbiota on vaccination and possible mechanisms. Gut Pathog. 2023;15(1):27.
185	H Seong, BK Choi, YH Han, et al. Gut microbiota as a potential key to modulating humoral immunogenicity of new platform COVID-19 vaccines. Signal Transduct Target Ther. 2023;8(1):178.
186	A Jordan, SR Carding, LJ Hall. The early-life gut microbiome and vaccine efficacy. Lancet Microbe. 2022;3(10):e787-e794.
187	F Zhu, S Huang, X Liu, et al. Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2023;11(12):1075-1088.
188	K Krasaewes, R Chaiwarith, N Chattipakorn, SC Chattipakorn. Profiles of gut microbiota associated with clinical outcomes in patients with different stages of SARS-CoV-2 infection. Life Sci. 2023;332:122136.
189	M Brīvība, L Silami?ele, L Birzniece, et al. Gut microbiome composition and dynamics in hospitalized COVID-19 patients and patients with post-acute COVID-19 syndrome. Int J Mol Sci. 2024;25(1):567.
190	V Peters, E van de Steeg, J van Bilsen, M Meijerink. Mechanisms and immunomodulatory properties of pre- and probiotics. Benef Microbes. 2019;10(3):225-236.
191	YS Handajani, Y Turana, Y Yogiara, et al. Effects of Tempeh probiotics on elderly with cognitive impairment. Front Aging Neurosci. 2022;14:891773.
192	Y Sun, K Wang, W Zhao. Gut microbiota in perioperative neurocognitive disorders: current evidence and future directions. Front Immunol. 2023;14:1178691.
193	T Zhang, X Wu, B Liu, H Huang, C Zhou, P Liang. The contribution of probiotics for the double-edge effect of cefazolin on postoperative neurocognitive disorders by rebalancing the gut microbiota. Front Neurosci. 2023;17:1156453.
194	X Yang, D Yu, L Xue, H Li, J Du. Probiotics modulate the microbiota-gut-brain axis and improve memory deficits in aged SAMP8 mice. Acta Pharm Sin B. 2020;10(3):475-487.
195	R Naomi, H Embong, F Othman, HF Ghazi, N Maruthey, H Bahari. Probiotics for Alzheimer's disease: a systematic review. Nutrients. 2021;14(1):20.
196	P Roman, AF Estévez, A Miras, et al. A pilot randomized controlled trial to explore cognitive and emotional effects of probiotics in fibromyalgia. Sci Rep. 2018;8(1):10965.
197	H Valdebenito-Navarrete, V Fuentes-Barrera, CT Smith, et al. Can probiotics, particularly Limosilactobacillus fermentum UCO-979C and Lacticaseibacillus rhamnosus UCO-25A, be preventive alternatives against SARS-CoV-2. Biology (Basel). 2023;12(3):384.
198	S Su, Y Zhao, N Zeng, et al. Epidemiology, clinical presentation, pathophysiology, and management of long COVID: an update. Mol Psychiatry. 2023;28(10):4056-4069.
199	AB Pomilio, AA Vitale, AJ Lazarowski. COVID-19 and Alzheimer's disease: neuroinflammation, oxidative stress, ferroptosis, and mechanisms involved. Curr Med Chem. 2023;30(35):3993-4031.
200	AM Fratta Pasini, C Stranieri, D Girelli, F Busti, L Cominacini. Is ferroptosis a key component of the process leading to multiorgan damage in COVID-19. Antioxidants (Basel). 2021;10(11):1677.
201	R Zhang, C Sun, X Chen, et al. COVID-19-related brain injury: the potential role of ferroptosis. J Inflamm Res. 2022;15:2181-2198.
202	SS Jankauskas, U Kansakar, C Sardu, et al. COVID-19 causes ferroptosis and oxidative stress in human endothelial cells. Antioxidants (Basel). 2023;12(2):326.
203	C Peleman, S Van Coillie, S Ligthart, et al. Ferroptosis and pyroptosis signatures in critical COVID-19 patients. Cell Death Differ. 2023;30(9):2066-2077.